SCHEMBL3318567

SCHEMBL3318567

Clc1cc2cnccc2cc1SC1CCCN(Cc2cccnc2)C1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 9/20 0.49
ROCK1 Q13464 5/20 0.49
CHRNB2 P17787 1/20 0.45
CHRNA4 P43681 1/20 0.45
ALDH1A1 P00352 2/20 0.44
MAPT P10636 1/20 0.44
HTT P42858 1/20 0.44
CCR2 P41597 2/20 0.43
PDE2A O00408 1/20 0.43
MAPK1 P28482 1/20 0.43
DRD2 P14416 1/20 0.39
DRD4 P21917 1/20 0.39
DRD3 P35462 1/20 0.39
KDM4E B2RXH2 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
CASP1 P29466 1/20 0.39
CASP4 P49662 1/20 0.39
CASP5 P51878 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3313618 0.94 ROCK2 (0.56) ROCK2ROCK1ALDH1A1CCR2
SCHEMBL3315519 0.94 ROCK2 (0.44) ROCK2ROCK1CHRNB2CHRNA4ALDH1A1
SCHEMBL3318778 0.92 ROCK2 (0.48) ROCK2ROCK1ALDH1A1MAPTCCR2
SCHEMBL3315515 0.90 ROCK2 (0.54) ROCK2ROCK1ALDH1A1HTTCCR2
SCHEMBL3316763 0.90 ROCK2 (0.48) ROCK2ROCK1MAPTHTTCCR2
SCHEMBL3313478 0.89 ROCK2 (0.46) ROCK2ROCK1MAPTHTTCCR2
SCHEMBL3319907 0.88 ROCK2 (0.45) ROCK2ROCK1CCR2PDE2ADRD4
SCHEMBL3313614 0.88 ROCK2 (0.50) ROCK2ROCK1CCR2
SCHEMBL13399051 0.88 CHRNB2 (0.46) ROCK2ROCK1CHRNB2CHRNA4DRD2
SCHEMBL3311726 0.86 ROCK2 (0.52) ROCK2ROCK1ALDH1A1MAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748614-B2 Substituted isoquinoline and isoquinolinone derivatives SANOFI (FR) 2014-06-10 US disclosed
US-8748614-B2 Substituted isoquinoline and isoquinolinone derivatives SANOFI (FR) 2014-06-10 US disclosed
US-8748614-B2 Substituted isoquinoline and isoquinolinone derivatives SANOFI (FR) 2014-06-10 US disclosed
US-20100105650-A1 Substituted isoquinoline and isoquinolinone derivatives SANOFI-AVENTIS (FR) 2010-04-29 US disclosed
US-20100105650-A1 Substituted isoquinoline and isoquinolinone derivatives SANOFI-AVENTIS (FR) 2010-04-29 US disclosed
US-20100105650-A1 Substituted isoquinoline and isoquinolinone derivatives SANOFI-AVENTIS (FR) 2010-04-29 US disclosed
EP-2114920-A1 SUBSTITUTED ISOQUINOLINE AND ISOQUINOLINONE DERIVATIVES Sanofi-Aventis (FR) 2009-11-11 EP disclosed
WO-2008077552-A1 SUBSTITUTED ISOQUINOLINE AND ISOQUINOLINONE DERIVATIVES SANOFI-AVENTIS (FR) 2008-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100105650-A1 Substituted isoquinoline and isoquinolinone derivatives MYLK2, MYLK, MYLK3 ROCK2 6/4885ROCK1 5/4885CHRNB2 817/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.